The company soon plans to start a phase 3 trial for the vaccine, mRNA-1038, in adults 50 and older. The vaccine, in early and mid-stage studies, generated a similar or greater immune response relative to two current flu shots. In terms of SARS-CoV-2, it achieved neutralizing antibody titers similar to the bivalent COVID-19 booster. No new side effects were identified beyond those seen with standalone flu and COVID-19 shots.
Moderna aims to secure regulatory approval for the vaccine in 2025.
“We are excited to move combination respiratory vaccines into Phase 3 development and look forward to partnering with public health officials to address the significant seasonal threat posed to people by these viruses,” the company’s CEO, Stephane Bancel, said in a statement.
Pfizer is also working to develop a combination shot targeting the respiratory viruses.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
